arrow
A

Akash Patnaik

Department of Medicine
H指数:31
被引数:5,663

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer

HLA class I expression塑造前列腺癌的肿瘤免疫微环境并影响其预后

2025-10-250
OA
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes

更正:自然杀伤细胞浸润在前列腺癌中预测患者预后改善

2025-08-120
OAAI
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
2023-09-0127
OA
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
2023-03-0124
OA
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
2021-12-1514
OA
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)

前列腺癌患者 (OSPREY) 中前列腺特异性膜抗原PET/CT与18F-DCFPyL的诊断准确性的2/3期前瞻性多中心研究

2021-07-01245
OA
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)

免疫疗法的观点: 免疫疗法桥 (意大利2020年12月2至3日) 的会议报告

2021-06-023
OAAI
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (December 4th-5th, 2019, Naples, Italy)
2021-01-063
OAAI
Pan-cancer image-based detection of clinically actionable genetic alterations (vol 1, pg 789, 2020)
2020-11-030
OAAI
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (vol 45, pg 747, 2013)
2020-09-031
OAAI
Pan-cancer image-based detection of clinically actionable genetic alterations

基于泛癌症图像的临床可行遗传改变检测

2020-07-27360
OAAI